Francesca Martella1, Carlotta Bacci1, Clara Giordano1, Francesco Montagnani1, Elena Gelain2, Loredana Rabatti3, Luisa Fioretto1. 1. SOC Oncologia Medica, Dipartimento Oncologico Azienda Sanitaria Firenze, Istituto Toscano Tumori, Piazza Santa Maria Nuova 1, 50100, Firenze, Italia. 2. Data Manager Clinical Research Group Dipartimento Oncologico Azienda Sanitaria Firenze, Presso Ospedale Santa Maria Annunziata, Via dell'Antella 58, Bagno a Ripoli, Firenze, Italia. 3. Dipartimento del Farmaco Azienda Sanitaria Firenze, Farmacia ospedaliera Ospedale Santa Maria Annunziata, Via dell'Antella 58, Bagno a Ripoli, Firenze, Italia.
Abstract
AIM: EMA licensed eribulin mesylate in 2011 for women with advanced breast cancer already treated with at least two lines of chemotherapy, including anthracyclines and taxanes. Azienda Sanitaria Firenze experience is reported to assess the efficacy and safety of eribulin in the real-life setting. PATIENTS & METHODS: Eribulin was infused as per indication. All women treated in the last 2 years were reviewed. RESULTS: A total of 27 women received eribulin. All but one was pretreated with anthracyclines, 97% with taxanes and 87% with capecitabine. Median age was 63 years (range: 27-80). A median of four cycles of eribulin were infused (range: 2-10). Overall response rate was 30% with a 45% of clinical benefit (response plus stable disease for at least 24 weeks). Toxicities have been as expected. Severe toxicities were rare, with one patient experiencing sepsis and 18% developing grade 3 asthenia. CONCLUSION: Eribulin maintains its activity out of clinical trials, without unexpected toxicities.
AIM: EMA licensed eribulin mesylate in 2011 for women with advanced breast cancer already treated with at least two lines of chemotherapy, including anthracyclines and taxanes. Azienda Sanitaria Firenze experience is reported to assess the efficacy and safety of eribulin in the real-life setting. PATIENTS & METHODS: Eribulin was infused as per indication. All women treated in the last 2 years were reviewed. RESULTS: A total of 27 women received eribulin. All but one was pretreated with anthracyclines, 97% with taxanes and 87% with capecitabine. Median age was 63 years (range: 27-80). A median of four cycles of eribulin were infused (range: 2-10). Overall response rate was 30% with a 45% of clinical benefit (response plus stable disease for at least 24 weeks). Toxicities have been as expected. Severe toxicities were rare, with one patient experiencing sepsis and 18% developing grade 3 asthenia. CONCLUSION: Eribulin maintains its activity out of clinical trials, without unexpected toxicities.
Entities:
Keywords:
eribulin; metastatic breast cancer; real-life setting
Authors: Francesco Giotta; Luigi Acito; Giampiero Candeloro; Pietro Del Medico; Gennaro Gadaleta-Caldarola; Guido Giordano; Rossana Gueli; Antonio Lugini; Valentina Magri; Marta Mandarà; Giovanna Masci; Salvatore Pisconti; Mirco Pistelli; Anna Rizzi; Nello Salesi; Alessio Schirone; Giovanni Scognamiglio; Maria Tedeschi; Patrizia Zucchinelli Journal: Oncologist Date: 2016-10-14